Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 12/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000445 | 0.91 | AKT3 (0.65) | AKT3HDAC1RAB9A | |
| SCHEMBL5000272 | 0.89 | AKT3 (0.61) | AKT3HDAC1RAB9AHDAC6 | |
| SCHEMBL5003908 | 0.89 | AKT3 (0.74) | AKT3HDAC1RAB9A | |
| SCHEMBL4996971 | 0.89 | AKT3 (0.74) | AKT3HDAC1RAB9A | |
| SCHEMBL4919817 | 0.88 | AKT3 (0.57) | AKT3HDAC1HDAC3HDAC4HDAC6 | |
| SCHEMBL5006439 | 0.87 | AKT3 (0.76) | AKT3RAB9A | |
| SCHEMBL6032999 | 0.86 | AKT3 (0.67) | AKT3RAB9A | |
| SCHEMBL4996241 | 0.85 | AKT3 (0.78) | AKT3HDAC1 | |
| SCHEMBL5003717 | 0.84 | AKT3 (1.00) | AKT3HDAC1 | |
| SCHEMBL5006017 | 0.84 | AKT3 (0.71) | AKT3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1708697-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1708697-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005074642-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | CYP11B2, CYP11B1, REN | AKT3 1872/4885HDAC1 261/4885RAB9A 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.